OakChart

Spyre Therapeutics Inc

SYREHealthcare·Biotechnology·USA·Large·NASD·Nov 11 • 3:30 PM ET

106.67+2.19 (2.09%)
2026-11-11 21:30 CET
Market cap
9,922.38 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-253.16 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-3.08
P/E
-
Compare

Price

SYRE against its 20, 50 and 200-day averages
2050200beatmiss
40.0060.0080.00100.002.2M4.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SYREclose 106.6720-day 95.6750-day 90.83200-day 75.97106.6752w high

3.6% under the 52-week high of 110.64 on 9 Nov 2026. 52-week low 21.63 on 11 Nov 2025. Last 15 sessions, 24.7% high to low

Volume 0.52× normal · the line is the 50-bar volume average

Profile

SYRE
52-week range, 96% of the way up
21.63110.64

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

IndexRUT
Employees102
IPOApr 07, 2016
Beta3.21
ATR, 14d5.11
Rel volume0.52
Short float13.62%
Insider own10.22%
Inst own105.26%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap10.13B
Enterprise Value9.20B
Income-253.16M
Sales0.00M
Book/sh10.06
Cash/sh11.29
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees102
IPOApr 07, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B10.60
P/C9.45
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio27.40
Current Ratio27.40
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.08
EPS next Y-3.81
EPS next Q-1.01
EPS this Y-57.46%
EPS next Y-22.36%
EPS next 5Y-
EPS past 3/5Y57.01% 44.61%
Sales past 3/5Y- -
EPS Y/Y TTM-41.56%
Sales Y/Y TTM-
EPS Q/Q-490.87%
Sales Q/Q-
EarningsNov 03 AMC
EPS/Sales Surpr.-14.31% -

Ownership

Insider Own10.22%
Insider Trans-33.84%
Inst Own105.26%
Inst Trans13.44%
ROA-31.56%
ROE-33.61%
ROIC-24.07%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2011.49%
SMA5017.44%
SMA20040.41%
Trades-

Technical

Shs Outstand89.95M
Shs Float85.27M
Short Float13.62%
Short Ratio9.32
Short Interest11.62M
52W High110.64 -3.59%
52W Low21.63 393.14%
Volatility6.39% 5.14%
ATR (14)5.11
RSI (14)64.10
Beta3.21
Rel Volume0.52
Avg Volume1.25M
Volume603,503

Performance

Perf Week7.70%
Perf Month32.59%
Perf Quarter4.73%
Perf Half Y39.78%
Perf YTD225.60%
Perf Year356.81%
Perf 3Y1023.98%
Perf 5Y-41.47%
Perf 10Y-28.05%
Recom1.18
Target Price122.67
Prev Close104.48
Price106.67
Change %2.09%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 12, 2026InitiatedUUBSBuy$120+12.5%
Oct 01, 2026InitiatedJJP MorganOverweight$110+3.1%
Jul 28, 2026DowngradeWWolfe ResearchOutperform → Peer Perform
Apr 14, 2026InitiatedRRaymond JamesStrong Buy$80-25.0%
Dec 18, 2025InitiatedMMizuhoOutperform$53-50.3%
Dec 17, 2025InitiatedCCitigroupBuy$64-40.0%
Sep 26, 2025InitiatedDDeutsche BankBuy$43-59.7%
Apr 08, 2025InitiatedLLeerink PartnersOutperform$45-57.8%
Mar 18, 2025InitiatedWWolfe ResearchOutperform$27-74.7%
Sep 04, 2024InitiatedWWedbushOutperform$45-57.8%

Peers

Mkt cap
TickerCompanyMkt cap
ABVXAbivax ADR8.00B
PTGXProtagonist Therapeutics Inc8.77B
ORKAOruka Therapeutics Inc7.22B
ROIVRoivant Sciences Ltd30.42B
JBIOJade Biosciences Inc1.05B
IMVTImmunovant Inc7.73B
ALMSAlumis Inc879.73M
ARQTArcutis Biotherapeutics Inc3.56B
MRKMerck & Co Inc362.27B
TEVATeva- Pharmaceutical Industries Ltd50.18B

Insider trading

latest 14 of 70
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
King-Jones HeidySee RemarksOct 01 '26Option Exercise14.5028,933419,52831,778Oct 02 09:30 PM
King-Jones HeidySee RemarksOct 01 '26Sale91.0328,9332,633,9022,845Oct 02 09:30 PM
Turtle CameronChief Executive OfficerOct 01 '26Sale92.0115,0001,380,105537,540Oct 02 09:29 PM
Burrows Scott LChief Financial OfficerSep 30 '26Option Exercise14.5017,500253,75097,262Oct 02 09:29 PM
Burrows Scott LChief Financial OfficerOct 01 '26Option Exercise14.507,500108,75087,262Oct 02 09:29 PM
Burrows Scott LChief Financial OfficerSep 30 '26Sale89.8917,5001,573,07579,762Oct 02 09:29 PM
Burrows Scott LChief Financial OfficerOct 01 '26Sale91.837,500688,75679,762Oct 02 09:29 PM
CAMERON TURTLEDirectorOct 01 '26Proposed Sale89.0345,0004,006,350Oct 01 04:36 PM
HEIDY KING-JONESOfficerOct 01 '26Proposed Sale89.0329,3352,611,695Oct 01 04:30 PM
SCOTT BURROWSOfficerSep 30 '26Proposed Sale89.8917,5001,573,157Sep 30 04:03 PM
King-Jones HeidySee RemarksSep 01 '26Option Exercise14.5027,999405,98630,844Sep 03 09:34 PM
King-Jones HeidySee RemarksSep 02 '26Option Exercise14.504005,8003,245Sep 03 09:34 PM
King-Jones HeidySee RemarksSep 01 '26Sale87.3127,9992,444,5292,845Sep 03 09:34 PM
King-Jones HeidySee RemarksSep 02 '26Sale90.0040036,0002,845Sep 03 09:34 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 198

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-0.940-0.822-0.9400.000.0014
2026Q22026-08-04-0.360-0.759-0.4270.000.0015
2026Q12026-05-05-0.740-0.666-0.8790.000.0015
2025Q42026-02-19-0.700-0.709-0.6900.000.0014
2025Q32025-11-04-0.150-0.761-0.1840.000.0012
2025Q22025-08-05-0.490-0.754-0.6050.000.0011
2025Q12025-05-08-0.600-0.841-0.5990.000.0010
2024Q42025-02-27-0.810-0.986-0.7900.003.0011
2024Q32024-11-07-1.360-0.824-1.0560.000.009
2024Q22024-08-07-0.860-0.950-0.5900.006.677
2024Q12024-05-09-1.200-1.049-0.7230.000.007
2023Q42024-02-29-4.050-0.72711.5790.000.376
2023Q32023-11-09-9.340-0.600-9.3410.00-2
2023Q22023-08-11-56.750-3.485-56.7890.690.202
2023Q12023-05-11-4.550-4.500-4.8860.200.183
2022Q42023-03-02-5.000-5.708-7.2010.170.136

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-61.250-61.473-61.2320.000.26
2020FY-38.000-37.107-37.8910.000.00
2021FY-25.000-24.969-25.02218.7418.36
2022FY-24.750-26.917-24.8622.332.23
2023FY-49.120-7.508-13.7570.891.12
2024FY-3.180-4.248-3.1800.002.61
2025FY-1.980-2.066-1.9800.000.00
2026FY--3.118--0.00
2027FY--3.815--0.00
2028FY--4.482--0.00
2029FY--5.037--57.33
2030FY--5.010--152.41

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-048000.000.000.00
2026Q4S2026-11-038000.000.000.00
2026Q4S2026-10-298000.000.000.00
2026Q4S2026-10-209000.000.000.00
2026Q4S2026-10-098000.000.000.00
2026Q4S2026-09-307000.000.000.00
2026Q4S2026-09-046000.000.000.00
2026Q4S2026-08-137000.000.000.00
2026Q4S2026-08-058000.000.000.00
2026Q4S2026-05-058000.000.000.00
2026Q4S2026-02-258000.000.000.00
2026Q4S2026-02-207000.000.000.00
2026Q4S2025-11-114000.000.000.00
2026Q4S2025-11-104000.000.000.00

Estimate history

EPS, annual-45-53.245-61.232-37.891-25.022-24.862-13.757-3.18-1.976-3.0832
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.056-0.79-0.599-0.605-0.184-0.69-0.879-0.427-1.087
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual5.2053.8880018.7392.3290.886000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.6670.9661.1631.9181.9742.61436.05760.25778.1989.954
Period201720182019202020212022202320242025MRQ
Shares, quarterly51.39660.25760.27660.73660.83578.1978.8488.06489.954
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.892.3318.740.000.003.89
Cost of Goods Sold Incl. D&A0.000.000.000.961.962.001.620.90-
Gross Profit0.000.000.00-0.080.3616.74-1.62-0.90-
Selling, General and Administrative Excl. Other320.17219.56208.57117.5385.1582.3979.8679.4349.06
Research and Development259.72171.65162.7984.0558.5857.0759.6464.6036.72
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-320.17-219.56-208.57-117.61-84.78-65.65-81.48-80.33-45.46
Interest Expense0.000.000.00-----0.00
Unusual Expense42.200.000.00224.670.000.000.00--
Net Income Before Taxes-263.86-155.22-207.97-338.82-83.95-65.66-80.89-78.25-44.35
Income Taxes0.00-0.010.05-0.03-0.140.140.000.000.00
Consolidated Net Income-253.16-126.54-149.56-94.88-83.81-65.80-80.89-78.25-44.35
Net Income From Continuing Operations-253.16-126.54-149.56-94.88-83.81-65.80-80.89-78.25-44.35
Net Income-253.16-126.54-149.56-94.88-83.81-65.80-80.89-78.25-44.35
EPS (Recurring)-2.53-1.98-3.189.05-24.86-25.02-37.89-61.23-53.25
EPS (Basic, Before Extraordinaries)-3.08-1.98-3.18-13.76-24.86-25.02-37.89-61.23-53.25
EPS (Diluted)-3.08-1.98-3.18-13.76-24.86-25.02-37.89-61.23-53.25
EBITDA-320.17-219.56-208.57-116.65-82.82-63.65-79.86-79.43-45.17
Non-Operating Income (Expense)98.5164.340.603.470.83-0.010.592.081.11
Other After Tax Adjustments10.7028.6658.46243.910.000.000.000.000.00
Stock Option Compensation Expense47.4336.5922.8711.255.625.876.224.884.05
Price To Earnings Ratio--2.53------
Price To Sales Ratio---167.5216.2816.67--40.11
Gross Margin----8.8015.6789.32---
Operating Margin----13,274.49-3,640.23-350.33---1,169.32
Net Margin----10,709.14-3,598.75-351.14---1,140.64
Shares Outstanding89.9578.1960.2636.062.611.971.921.160.97
Market Capitalization9,922.389,922.381,366.6887.1327.67234.44377.44222.21180.81

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other105.7281.6475.6457.1756.8951.9453.5761.25
Research and Development89.1765.5060.4144.6445.2540.1541.6250.48
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-105.72-81.64-75.64-57.17-56.89-51.94-53.57-61.25
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.0042.20-40.400.60-2.400.00
Net Income Before Taxes-96.12-36.20-69.00-62.53-11.18-36.72-44.79-56.30
Income Taxes0.000.000.000.000.000.00-0.010.00
Consolidated Net Income-96.12-36.20-69.00-51.83-11.18-36.72-36.09-43.67
Net Income From Continuing Operations-96.12-36.20-69.00-51.83-11.18-36.72-36.09-43.67
Net Income-96.12-36.20-69.00-51.83-11.18-36.72-36.09-43.67
EPS (Recurring)-1.09-0.43-0.88-0.30-0.65-0.60-0.63-0.79
EPS (Basic, Before Extraordinaries)-1.09-0.43-0.88-0.69-0.18-0.60-0.60-0.79
EPS (Diluted)-1.09-0.43-0.88-0.69-0.18-0.60-0.60-0.79
EBITDA-105.72-81.64-75.64-57.17-56.89-51.94-53.57-61.25
Non-Operating Income (Expense)9.6045.446.6436.845.3115.826.384.96
Other After Tax Adjustments0.000.000.0010.700.000.008.6912.62
Stock Option Compensation Expense14.1713.5112.816.949.579.387.00-
Price To Earnings Ratio-------2.53
Shares Outstanding89.9588.0678.8478.1960.8360.7460.2860.26
Market Capitalization9,922.387,709.773,961.572,541.921,012.32903.49972.251,366.68

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments756.53603.09339.2855.7193.13146.2771.9574.5150.30
Short Term Receivables0.000.000.000.380.810.000.000.303.08
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets21.255.392.256.174.953.522.561.861.61
Total Current Assets777.78608.47341.5362.2698.89149.7974.5076.6754.99
Net Property, Plant & Equipment0.000.000.007.259.159.947.171.020.85
Total Investments and Advances0.000.000.321.551.841.841.500.000.00
Intangible Assets0.00-------0.00
Other Assets0.000.010.010.090.040.050.010.050.23
Total Assets777.78608.48341.8671.14109.93161.6283.1877.7456.08
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.640.850.350.380.000.00
Accounts Payable8.900.670.900.683.322.253.150.660.39
Other Current Liabilities49.7853.3931.0813.3415.9713.8414.839.585.24
Total Current Liabilities58.6954.0631.9814.6620.1416.4418.3610.245.63
Long Term Debt0.000.0084.564.004.625.174.740.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities3.8636.6241.312.181.220.170.000.070.11
Total Liabilities62.5590.68157.8420.8425.9821.7923.1010.315.74
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value155.82155.82184.930.000.000.000.000.000.00
Common Equity559.42361.98-0.9150.3083.94139.8360.0867.4350.34
Total Shareholders Equity715.24517.80184.0250.3083.94139.8360.0867.4350.34
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity715.24517.80184.0250.3083.94139.8360.0867.4350.34
Total Liabilities & Stockholders Equity777.78608.48341.8671.14109.93161.6283.1877.7456.08
Book Value Per Share7.156.01-0.0319.2442.5272.8951.6469.8375.49
Tangible Book Value Per Share7.156.01-0.0319.2442.5272.8951.6469.8375.49
Full-Time Employees10265306910190766143
Price to Book Ratio10.386.97-0.350.412.792.703.702.681.61
Return on Assets-18.26-31.47-45.95-92.58-48.46-66.09-97.26-66.28-44.24
Return on Equity-20.53-42.62-80.99-124.87-58.81-80.93-122.74-75.32-48.08
Return on Invested Capital-17.69-28.88-35.33-154.33-74.30-55.79-120.72-65.77-54.11
Quick Ratio13.2511.2610.684.254.919.114.067.499.77
Current Ratio13.2511.2610.684.254.919.114.067.499.77

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-263.86-155.20-208.02-338.79-83.81-65.80-80.89-78.25-44.35
Depreciation-0.000.000.961.962.001.620.900.29
Other Funds (Non Cash)16.20-8.2854.73243.127.218.256.034.564.66
Funds from Operations-247.66-163.48-153.28-94.70-74.64-55.55-73.23-72.80-39.39
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.49-5.93-4.53-5.21-5.501.83-2.547.107.20
Cash from Operating Activities-250.15-169.41-157.82-99.91-80.14-53.72-75.78-65.69-32.19
Capital Expenditures0.000.000.000.00-0.04-0.57-4.28-1.49-0.42
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses7.007.000.0015.470.000.000.000.000.00
Purchase or Sale of Investments-562.54-150.47-353.29-126.9057.05-22.05-3.32-0.25-14.81
Purchase of Investments-1,008.50-522.21-599.25-166.80-39.50-133.08-129.00-91.93-62.18
Sale Or Maturity of Investments445.96371.74245.9739.9096.55111.03125.6891.6847.37
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources63.000.000.003.040.000.000.000.000.00
Cash from Investing Activities-492.54-143.47-353.29-108.3957.01-22.62-7.60-1.74-15.23
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock816.24314.44412.74366.8843.101.90154.5365.7557.07
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock816.24314.44412.74366.8843.101.90154.5365.7557.07
Proceedsfrom Stock Options785.65311.13405.23366.470.000.000.000.0054.05
Issuance or Reduction of Debt, Net0.000.000.00-0.02-0.42-0.51-0.02-0.030.00
Change in Long Term Debt0.000.000.00-0.02-0.42-0.51-0.02-0.030.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-0.02-0.42-0.51-0.02-0.030.00
Net Financing Active Other Cash Flow-55.73-5.25-1.43-5.790.000.000.000.000.00
Other Financing Activities Uses-55.73-5.25-1.43-5.790.000.000.000.000.00
Cash from Financing Activities760.51309.19411.31361.0842.681.39154.5165.7257.07
Exchange Rate Effect-0.00-0.000.03-0.11-0.010.05--
Net Change in Cash17.83-3.70-99.79152.8019.44-74.9671.18-1.719.64
Free Cash Flow---157.82-99.91-80.18-54.29-80.06-67.18-32.62
Preferred Dividends (Cash Flow)----0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments1,071.911,145.35741.47756.53486.20526.58
Short Term Receivables5.805.804.600.003.603.50
Inventories0.000.000.000.000.000.00
Other Current Assets22.0221.8617.8921.2514.818.75
Total Current Assets1,099.731,173.00763.95777.78504.60538.83
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets1,099.731,173.00763.95777.78504.60538.83
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable9.475.725.698.907.463.71
Other Current Liabilities30.6857.5879.4749.7838.8279.35
Total Current Liabilities40.1463.3085.1658.6946.2783.06
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities8.058.567.983.863.230.00
Total Liabilities48.1971.8693.1462.5549.5083.06
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value146.43146.43155.82155.820.000.00
Common Equity905.11954.72514.99559.42455.10455.77
Total Shareholders Equity1,051.541,101.14670.81715.24455.10455.77
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,051.541,101.14670.81715.24455.10455.77
Total Liabilities & Stockholders Equity1,099.731,173.00763.95777.78504.60538.83
Book Value Per Share10.0610.846.537.157.487.50
Tangible Book Value Per Share10.0610.846.537.157.487.50
Full-Time Employees1301251121029587
Price to Book Ratio10.3813.597.054.382.232.76
Return on Assets-31.56-19.65-25.30-19.59-27.58-34.91
Return on Equity-33.61-21.61-29.26-22.03-32.63-41.00
Return on Invested Capital-9.14-3.29-10.29-7.25-2.46-8.06
Quick Ratio27.4018.538.9713.2510.906.49
Current Ratio27.4018.538.9713.2510.906.49

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-96.12-36.20-69.00-62.53-11.18-36.72
Other Funds (Non Cash)9.78-24.9511.2220.15-31.87-0.81
Funds from Operations-86.34-61.15-57.79-42.38-43.06-37.52
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital8.54-9.010.24-2.275.94-9.04
Cash from Operating Activities-77.80-70.16-57.54-44.65-37.12-46.56
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.007.000.000.00
Purchase or Sale of Investments-3.80-337.9026.58-247.4125.0072.00
Purchase of Investments-138.28-447.34-81.17-341.71-74.19-34.87
Sale Or Maturity of Investments134.48109.44107.7594.3099.19106.87
Other Uses0.000.000.000.000.000.00
Other Sources0.0040.0030.00-7.000.007.00
Cash from Investing Activities-3.80-297.9056.58-247.4125.0079.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00---0.00-
Change in Capital Stock35.12455.8212.43312.880.490.73
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock35.12455.8212.43312.880.490.73
Proceedsfrom Stock Options29.52435.249.75311.130.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-32.80-22.930.000.00-5.130.00
Other Financing Activities Uses-32.80-22.930.000.00-5.130.00
Cash from Financing Activities2.32432.8912.43312.88-4.640.73
Exchange Rate Effect---0.000.000.00
Net Change in Cash-79.2864.8211.4620.82-16.7633.17
Free Cash Flow-77.80-70.16-57.54--37.12-

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.62%11.6M85.3M1.20M
2026-10-1515.09%12.5M82.9M1.20M
2026-09-3016.25%12.8M79.0M1.14M
2026-09-1515.35%12.1M79.0M1.30M
2026-08-3115.01%11.9M79.0M1.31M
2026-08-1414.88%11.8M79.0M1.26M
2026-07-3115.44%12.1M78.7M1.32M
2026-07-1516.15%12.5M77.5M1.39M
2026-06-3017.62%13.6M77.4M1.42M
2026-06-1516.30%12.6M77.4M1.16M
2026-05-2916.33%12.6M77.3M1.09M
2026-05-1516.07%12.4M77.3M1.10M
2026-04-3016.22%12.2M75.3M1.01M
2026-04-1516.51%11.7M70.7M888.66K
2026-03-3116.23%10.4M64.3M741.98K
2026-03-1315.55%10.0M64.3M724.71K
2026-02-2715.53%10.0M64.3M746.57K
2026-02-1315.34%9.9M64.3M708.16K
2026-01-3014.79%10.0M67.5M703.10K
2026-01-1514.91%10.1M67.5M803.23K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call30.0074.0078.600.006.2150.000.000.997-0.0280.001
call35.0069.0073.600.005.4390.000.000.956-0.4870.015
call40.0064.0068.600.004.9050.000.000.950-0.4840.017
call45.0059.0063.600.004.3820.000.000.943-0.4780.019
call50.0054.0058.6025.983.9183.000.000.936-0.4710.021
call55.0049.0053.6019.403.5011.000.000.928-0.4620.023
call60.0044.0048.600.003.1200.000.000.919-0.4510.025
call65.0039.0043.600.002.7960.000.000.875-0.7040.034
call70.0034.0038.6019.002.4413.000.000.860-0.6810.037
call75.0029.0033.7011.002.16525.000.000.843-0.6530.040
call80.0024.0028.7020.201.86924.000.000.822-0.6210.043
call85.0019.0023.707.161.53711.000.000.797-0.5830.047
call90.0014.0018.8020.601.33616.000.000.765-0.5380.051
call95.0010.5013.5011.900.9971100.000.724-0.4830.055
call1006.0010.505.001.0786.000.000.665-0.4040.060
call1053.407.003.240.8822.000.000.587-0.3370.065
call1101.004.904.900.93412.000.000.453-0.3530.066
call1150.004.902.001.25810.000.000.374-0.4410.063
call1200.004.902.001.48512.000.000.338-0.5070.061
call1250.004.900.001.6260.000.000.317-0.5470.060
call1300.004.900.001.8570.000.000.292-0.5990.057
call1350.001.804.201.4192.000.000.167-0.3340.042
call1400.004.903.701.6145.000.000.159-0.3600.040
call1450.004.906.101.6351.000.000.149-0.3600.039
call1500.004.900.001.7840.000.000.141-0.3740.037
call1550.004.900.001.9050.000.000.129-0.3750.035
call1600.004.900.001.9900.000.000.129-0.3960.035
put30.000.000.050.003.7320.000.00-0.009-0.0820.004
put35.000.004.900.005.4750.000.00-0.045-0.4680.016
put40.000.004.900.004.9040.000.00-0.051-0.4650.017
put45.000.004.900.004.3490.000.00-0.058-0.4580.019
put50.000.004.904.803.8843.000.00-0.066-0.4490.021
put55.000.004.900.003.4660.000.00-0.074-0.4400.023
put60.000.002.400.171.7802.000.00-0.020-0.0760.008
put65.000.004.900.003.5240.000.00-0.129-0.6700.035
put70.000.004.900.193.13048.000.00-0.146-0.6450.038
put75.000.004.901.252.90412.000.00-0.155-0.6470.040
put80.000.004.901.342.53455.000.00-0.176-0.6120.043
put85.000.004.904.602.21797.000.00-0.199-0.5790.047
put90.000.004.903.901.90345.000.00-0.227-0.5370.051
put95.000.004.902.001.56457.000.00-0.269-0.4810.055
put1000.004.908.001.19771.000.00-0.334-0.3940.060
put1051.304.903.000.8553.000.00-0.438-0.3270.065
put1104.208.0010.800.94624.000.00-0.547-0.3410.066
put1157.8012.500.001.0180.000.00-0.624-0.4260.063
put12012.0016.300.001.0690.000.00-0.660-0.4960.061
put12516.6021.400.001.2740.000.00-0.688-0.5450.059
put13021.5026.000.001.4220.000.00-0.708-0.5860.057
put13526.3031.000.001.5440.000.00-0.838-0.3070.041
put14031.3036.000.001.6880.000.00-0.849-0.3220.039
put14536.3041.000.001.8220.000.00-0.857-0.3350.037
put15041.3046.000.001.9490.000.00-0.864-0.3470.036
put15546.3051.000.002.0690.000.00-0.870-0.3570.035
put16051.3056.000.002.1820.000.00-0.876-0.3670.034

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-038-KCurrent report2026-11-03SEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-09SCHEDULE 13D/ASEC
2026-10-078-KCurrent report2026-10-05SEC
2026-10-06424B5SEC
2026-10-05424B5SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-10-01SCHEDULE 13GSEC
2026-09-30144Filing for proposed sale of securities under Rule 144.SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-258-KCurrent report2026-08-25SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10004.70M3
2026-09007.65M6
2026-08004.55M4
2026-07002.70M3
2026-0600405.18M6
2026-050013.52M4
2026-04001.51M3
2026-0300734.49K2
2026-0200492.05K1
2026-0100460.13K1
2025-1200435.36K1
2025-11001.05M1

Institutional holders

Manager% owned
FMR LLC15.31%
BlackRock, Inc.7.49%
PERCEPTIVE ADVISORS LLC4.97%
RTW INVESTMENTS, LP4.90%
Paradigm Biocapital Advisors LP4.42%
VANGUARD CAPITAL MANAGEMENT LLC3.97%
STATE STREET CORP3.52%
Venrock Adviser, LLC3.44%
PRICE T ROWE ASSOCIATES INC /MD/3.41%
DRIEHAUS CAPITAL MANAGEMENT LLC3.22%

Funds

Fund% owned
SMALLCAP World Fund Inc3.20%
Fidelity Growth Company Fund3.13%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.86%
iShares Russell 2000 ETF2.20%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.53%
VANGUARD SMALL-CAP INDEX FUND1.03%
Fidelity Advisor Biotechnology Fund0.99%
Fidelity Small Cap Index Fund0.94%
Fidelity Growth Company K6 Fund0.91%
Fidelity Small Cap Growth Fund0.90%

OakChart. SYRE. Cached 15 minutes.